High tumor burden in patients with non-small-cell lung cancer: a Delphi survey among Spanish oncologists.

Aim: To define high tumor burden (HTB) in non-small-cell lung cancer. Methods: A total of five oncologists initiated the project, selecting 66 participants, and elaborated a questionnaire with 26 statements using the Delphi method with a 9-point Likert scale of agreement. Results: Factors with moderate strength of consensus were identified, including a sum of the longest diameter of lesions ≥10 cm, elevated LDH, hepatic involvement, lymphangitis carcinomatosis, brain involvement unapproachable with local techniques and pericardial effusion. There was a consensus against increases in tumor markers and asymptomatic brain involvement being related to HTB. HTB was considered a relevant factor for treatment selection supporting the choice of combination regimens versus immunotherapy only. Conclusion: In this Delphi study, experts defined several factors associated with HTB in non-small cell lung cancer.

[1]  S. Palanca,et al.  Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital , 2023, Cancers.

[2]  S. Shirvani,et al.  Disease Burden on PET Predicts Outcomes for Advanced NSCLC Patients Treated with First-Line Immunotherapy. , 2022, Clinical lung cancer.

[3]  X. Nie,et al.  Efficacy and safety of anti‐PD‐1/PD‐L1 in combination with chemotherapy or not as first‐line treatment for advanced non‐small cell lung cancer: A systematic review and network meta‐analysis , 2021, Thoracic cancer.

[4]  B. Lamprecht,et al.  First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes , 2021, Cancers.

[5]  Shucai Wang,et al.  Prognosis and role of clinical and imaging features in patients with malignant pericardial effusion: a single-center study in China , 2021, BMC Cardiovascular Disorders.

[6]  J. Cooper,et al.  Paraneoplastic Syndromes in Lung Cancers: Manifestations of Ectopic Endocrinological Syndromes and Neurologic Syndromes. , 2021, Thoracic surgery clinics.

[7]  C. Liao,et al.  High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients , 2021, Cancers.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  A. Ardizzoni,et al.  PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination. , 2021, Immunotherapy.

[10]  M. McKay.  Brain metastases: increasingly precision medicine—a narrative review , 2021, Annals of translational medicine.

[11]  Y. Kodera,et al.  The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score , 2020, International Journal of Clinical Oncology.

[12]  L. Sehn,et al.  Initial Treatment of High Tumor Burden Follicular Lymphoma. , 2020, Hematology/oncology clinics of North America.

[13]  L. Landi,et al.  First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. , 2020, European journal of cancer.

[14]  K. Ichikado,et al.  Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors , 2019, Thoracic cancer.

[15]  M. Kudo.  A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE , 2019, Liver Cancer.

[16]  J. Molina,et al.  Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. , 2019, Mayo Clinic proceedings.

[17]  G. Rustin,et al.  Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome , 2019, Annals of Surgical Oncology.

[18]  S. Plaza Canteli,et al.  Metastatic spinal cord compression: Incidence, epidemiology and prognostic factors. , 2019, Revista clinica espanola.

[19]  N. Reguart,et al.  SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018) , 2018, Clinical and Translational Oncology.

[20]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  W. Cheung,et al.  Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer , 2018, Medical Oncology.

[22]  G. Salles,et al.  Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. , 2018, Blood.

[23]  Zhen-hua Hu,et al.  High expressions of BCL6 and Lewis y antigen are correlated with high tumor burden and poor prognosis in epithelial ovarian cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[24]  Ping Yang,et al.  Prognostic effect of liver metastasis in lung cancer patients with distant metastasis , 2016, Oncotarget.

[25]  Jihyoun Jeon,et al.  Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, 1973–2010 , 2015, PloS one.

[26]  D. Gerber,et al.  Baseline tumour measurements predict survival in advanced non-small cell lung cancer , 2013, British Journal of Cancer.